XCL1 expression correlates with CD8-positive T cells infiltration and PD-L1 expression in squamous cell carcinoma arising from mature cystic teratoma of the ovary.
B7-H1 Antigen
/ genetics
CD8-Positive T-Lymphocytes
/ immunology
Carcinoma, Squamous Cell
/ genetics
Chemokines, C
/ genetics
Female
Gene Expression Regulation, Neoplastic
/ immunology
Humans
Lymphocytes, Tumor-Infiltrating
/ immunology
Neoplasm Proteins
/ genetics
Ovarian Neoplasms
/ genetics
Teratoma
/ genetics
Journal
Oncogene
ISSN: 1476-5594
Titre abrégé: Oncogene
Pays: England
ID NLM: 8711562
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
07
11
2019
accepted:
19
02
2020
revised:
15
02
2020
pubmed:
3
3
2020
medline:
24
11
2020
entrez:
3
3
2020
Statut:
ppublish
Résumé
Molecular characteristics of carcinoma arising from mature cystic teratoma of the ovary (MCT) remain unclear due to its rarity. We analyzed RNA-sequencing data of 2322 pan-cancer [1378 squamous cell carcinomas (SCC), 6 adenosquamous carcinomas (ASC), and 938 adenocarcinomas (AC)] including six carcinomas arising from MCT (four SCCs, one ASC, and one AC). Hierarchical clustering and principal component analysis showed that gene expression profiles of carcinomas arising from MCT were different between each histological type and that gene expression profiles of SCCs arising MCT (MCT-SCCs) was apparently similar to those of lung SCCs. By epidermis-associated pathways activity based on gene set enrichment analysis, 1030 SCCs were divided into two groups: epidermis-signature high (head and neck, esophagus, and skin) and low (cervix, lung, and MCT). In addition to pan-SCC transcriptome analysis, cytokeratin profiling based on immunohistochemistry in the independent samples of 21 MCT-SCCs clarified that MCT-SCC dominantly expressed CK18, suggesting the origin of MCT-SCC was columnar epithelium. Subsequently, we investigated differentially expressed genes in MCT-SCCs compared with different SCCs and identified XCL1 was specifically overexpressed in MCT-SCCs. Through immunohistochemistry analysis, we identified XCL1 expression on tumor cells in 13/24 (54%) of MCT-SCCs but not in MCTs. XCL1 expression was also significantly associated with the number of tumor-infiltrating CD8-positive T cells and PD-L1 expression on tumor cells. XCL1 produced by tumor cells may induce PD1/PD-L1 interaction and dysfunction of CD8-positive T cells in tumor microenvironment. XCL1 expression may be a novel biomarker for malignant transformation of MCT into SCC and a biomarker candidate for therapeutic response to an anti-PD1/PD-L1 therapy.
Identifiants
pubmed: 32115573
doi: 10.1038/s41388-020-1237-0
pii: 10.1038/s41388-020-1237-0
pmc: PMC7176584
doi:
Substances chimiques
B7-H1 Antigen
0
CD274 protein, human
0
Chemokines, C
0
Neoplasm Proteins
0
XCL1 protein, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3541-3554Références
Hackethal A, Brueggmann D, Bohlmann MK, Franke FE, Tinneberg HR, Munstedt K. Squamous-cell carcinoma in mature cystic teratoma of the ovary: systematic review and analysis of published data. Lancet Oncol. 2008;9:1173–80.
pubmed: 19038764
Mori Y, Nishii H, Takabe K, Shinozaki H, Matsumoto N, Suzuki K, et al. Preoperative diagnosis of malignant transformation arising from mature cystic teratoma of the ovary. Gynecol Oncol. 2003;90:338–41.
pubmed: 12893196
Akazawa M, Onjo S. Malignant transformation of mature cystic teratoma: is squamous cell carcinoma different from the other types of neoplasm? Int J Gynecol Cancer. 2018;28:1650–6.
pubmed: 30358706
Amerigo J, Nogales FF Jr, Fernandez-Sanz J, Oliva H, Velasco A. Squamous cell neoplasms arising from ovarian benign cystic teratoma. Gynecol Oncol. 1979;8:277–83.
pubmed: 510996
Cooke SL, Ennis D, Evers L, Dowson S, Chan MY, Paul J, et al. The driver mutational landscape of ovarian squamous cell carcinomas arising in mature cystic teratoma. Clin Cancer Res. 2017;23:7633–40.
pubmed: 28954785
Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012;489:519–25.
Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015;517:576–82.
Cancer Genome Atlas Research Network. Integrated genomic and molecular characterization of cervical cancer. Nature. 2017;543:378–84.
Cancer Genome Atlas Research Network. Integrated genomic characterization of oesophageal carcinoma. Nature. 2017;541:169–75.
Hoadley KA, Yau C, Hinoue T, Wolf DM, Lazar AJ, Drill E, et al. Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer. Cell. 2018;173:291.e6–304.e6.
Campbell JD, Yau C, Bowlby R, Liu Y, Brennan K, Fan H, et al. Genomic, pathway network, and immunologic features distinguishing squamous carcinomas. Cell Rep. 2018;23:194.e6–212.e6.
Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, et al. Pembrolizumab versus Chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375:1823–33.
pubmed: 27718847
Ferris RL, Blumenschein G, Jr., Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375:1856–67.
Chung HC, Ros W, Delord JP, Perets R, Italiano A, Shapira-Frommer R, et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the Phase II KEYNOTE-158 Study. J Clin Oncol. 2019;37:1470–8.
pubmed: 30943124
Kudo T, Hamamoto Y, Kato K, Ura T, Kojima T, Tsushima T, et al. Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial. Lancet Oncol. 2017;18:631–9.
pubmed: 28314688
Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD, et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N. Engl J Med. 2018;379:341–51.
pubmed: 29863979
Li B, Cui Y, Nambiar DK, Sunwoo JB, Li R. The immune subtypes and landscape of squamous cell carcinoma. Clin Cancer Res. 2019;25:3528–37.
Chiang AJ, Chen MY, Weng CS, Lin H, Lu CH, Wang PH, et al. Malignant transformation of ovarian mature cystic teratoma into squamous cell carcinoma: a Taiwanese Gynecologic Oncology Group (TGOG) study. J Gynecol Oncol. 2017;28:e69.
pubmed: 28657230
pmcid: 5540728
Chakravarty D, Gao J, Phillips SM, Kundra R, Zhang H, Wang J, et al. OncoKB: a precision oncology knowledge base. JCO Precis Oncol. 2017;2017. https://doi.org/10.1200/PO.17.00011 .
Forbes SA, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H, et al. COSMIC: exploring the world’s knowledge of somatic mutations in human cancer. Nucleic Acids Res. 2015;43:D805–11.
pubmed: 25355519
Torres-Garcia W, Zheng S, Sivachenko A, Vegesna R, Wang Q, Yao R, et al. PRADA: pipeline for RNA sequencing data analysis. Bioinformatics. 2014;30:2224–6.
pubmed: 24695405
pmcid: 4103589
Nicorici D, Şatalan M, Edgren H, Kangaspeska S, Murumägi A, Kallioniemi O, et al. FusionCatcher—a tool for finding somatic fusion genes in paired-end RNA-sequencing data. 2014. https://doi.org/10.1101/011650 .
Eifert C, Pantazi A, Sun R, Xu J, Cingolani P, Heyer J, et al. Clinical application of a cancer genomic profiling assay to guide precision medicine decisions. Per Med. 2017;14:309–25.
pubmed: 28890729
pmcid: 5580078
Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med. 2017;377:2500–1.
pubmed: 29262275
pmcid: 6549688
Cristescu R, Mogg R, Ayers M, Albright A, Murphy E, Yearley J, et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science. 2018;362:eaar3593.
Keck MK, Zuo Z, Khattri A, Stricker TP, Brown CD, Imanguli M, et al. Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes. Clin Cancer Res. 2015;21:870–81.
pubmed: 25492084
Dorner BG, Dorner MB, Zhou X, Opitz C, Mora A, Guttler S, et al. Selective expression of the chemokine receptor XCR1 on cross-presenting dendritic cells determines cooperation with CD8+ T cells. Immunity. 2009;31:823–33.
pubmed: 19913446
Teng MW, Ngiow SF, Ribas A, Smyth MJ. Classifying cancers based on T-cell infiltration and PD-L1. Cancer Res. 2015;75:2139–45.
pubmed: 25977340
pmcid: 25977340
Fruman DA, Chiu H, Hopkins BD, Bagrodia S, Cantley LC, Abraham RT. The PI3K pathway in human disease. Cell. 2017;170:605–35.
pubmed: 28802037
pmcid: 5726441
Li F, Mao G, Tong D, Huang J, Gu L, Yang W, et al. The histone mark H3K36me3 regulates human DNA mismatch repair through its interaction with MutSalpha. Cell. 2013;153:590–600.
pubmed: 23622243
pmcid: 3641580
Ding H, Zhao J, Zhang Y, Yu J, Liu M, Li X, et al. Systematic analysis of drug vulnerabilities conferred by tumor suppressor loss. Cell Rep. 2019;27:3331.e6–44.e6.
Marcial-Rojas RA, Medina R. Cystic teratomas of the ovary; a clinical and pathological analysis of two hundred sixty-eight tumors. AMA Arch Pathol. 1958;66:577–89.
pubmed: 13582397
Hirakawa T, Tsuneyoshi M, Enjoji M. Squamous cell carcinoma arising in mature cystic teratoma of the ovary. Clinicopathologic and topographic analysis. Am J Surg Pathol. 1989;13:397–405.
pubmed: 2712191
Iwasa A, Oda Y, Kaneki E, Ohishi Y, Kurihara S, Yamada T, et al. Squamous cell carcinoma arising in mature cystic teratoma of the ovary: an immunohistochemical analysis of its tumorigenesis. Histopathology. 2007;51:98–104.
pubmed: 17542994
Lei Y, Takahama Y. XCL1 and XCR1 in the immune system. Microbes Infect. 2012;14:262–7.
pubmed: 22100876
Kelner GS, Kennedy J, Bacon KB, Kleyensteuber S, Largaespada DA, Jenkins NA, et al. Lymphotactin: a cytokine that represents a new class of chemokine. Science. 1994;266:1395–9.
pubmed: 7973732
Khurram SA, Whawell SA, Bingle L, Murdoch C, McCabe BM, Farthing PM. Functional expression of the chemokine receptor XCR1 on oral epithelial cells. J Pathol. 2010;221:153–63.
pubmed: 20225245
Kim M, Rooper L, Xie J, Rayahin J, Burdette JE, Kajdacsy-Balla AA, et al. The lymphotactin receptor is expressed in epithelial ovarian carcinoma and contributes to cell migration and proliferation. Mol Cancer Res. 2012;10:1419–29.
pubmed: 22964431
Suda K, Nakaoka H, Yoshihara K, Ishiguro T, Tamura R, Mori Y, et al. Clonal expansion and diversification of cancer-associated mutations in endometriosis and normal endometrium. Cell Rep. 2018;24:1777–89.
pubmed: 30110635
Tamura R, Yoshihara K, Saito T, Ishimura R, Martinez-Ledesma JE, Xin H, et al. Novel therapeutic strategy for cervical cancer harboring FGFR3-TACC3 fusions. Oncogenesis. 2018;7:4.
pubmed: 29358619
pmcid: 5833787
Ichikawa H, Nagahashi M, Shimada Y, Hanyu T, Ishikawa T, Kameyama H, et al. Actionable gene-based classification toward precision medicine in gastric cancer. Genome Med. 2017;9:93.
pubmed: 29089060
pmcid: 5664811
Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Disco. 2012;2:401–4.
Chitsazzadeh V, Coarfa C, Drummond JA, Nguyen T, Joseph A, Chilukuri S, et al. Cross-species identification of genomic drivers of squamous cell carcinoma development across preneoplastic intermediates. Nat Commun. 2016;7:12601.
pubmed: 27574101
pmcid: 5013636
Bray NL, Pimentel H, Melsted P, Pachter L. Near-optimal probabilistic RNA-seq quantification. Nat Biotechnol. 2016;34:525–7.
pubmed: 27043002
Caliński T, Harabasz J. A dendrite method for cluster analysis. Commun Stat Theory Methods. 1974;3:1–27.
Krzanowski WJ, Lai YT. A criterion for determining the number of groups in a data set using sum-of-squares clustering. Biometrics. 1988;44:23–4.
Sun J, Nishiyama T, Shimizu K, Kadota K. TCC: an R package for comparing tag count data with robust normalization strategies. BMC Bioinform. 2013;14:219.
Nishiwaki M, Yamamoto T, Tone S, Murai T, Ohkawara T, Matsunami T, et al. Genotyping of human papillomaviruses by a novel one-step typing method with multiplex PCR and clinical applications. J Clin Microbiol. 2008;46:1161–8.
pubmed: 18234872
pmcid: 2292906
Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348:203–13.
pubmed: 12529460
O’Malley DP, Yang Y, Boisot S, Sudarsanam S, Wang JF, Chizhevsky V, et al. Immunohistochemical detection of PD-L1 among diverse human neoplasms in a reference laboratory: observations based upon 62,896 cases. Mod Pathol. 2019;32:929–42.
pubmed: 30760860
pmcid: 6760643
John T, Liu G, Tsao MS. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors. Oncogene. 2009;28(Suppl 1):S14–23.
pubmed: 19680292